HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) | PA 17 291

Frequently Asked Questions (FAQs)

What is the HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) funding opportunity?

It is an NIH research grant opportunity (R01 mechanism) focused on improving how HIV drug resistance is understood and predicted in real-world treatment settings by linking viral genotype, viral phenotype, and patient outcomes.

What is the Funding Opportunity Number (FON) for this program?

The Funding Opportunity Number is PA-17-291.

What is the main goal of this NIH R01 opportunity?

The central goal is to fund studies that clarify how three types of evidence relate to each other in clinical practice: (1) viral genotype (resistance mutations identified by sequencing), (2) viral phenotype (laboratory drug-susceptibility behavior), and (3) actual patient outcomes (whether an antiretroviral regimen succeeds or fails). The intent is to strengthen the evidence base behind resistance interpretation and improve regimen selection and treatment success.

What does "genotype-phenotype-outcome correlation" mean in this context?

It refers to understanding how resistance mutations seen in HIV genetic sequencing (genotype) translate into measurable drug susceptibility in lab testing (phenotype), and how both of those relate to what happens clinically for a patient on therapy (outcome).

Why does the FOA emphasize that these three pieces of evidence may not line up neatly?

The announcement highlights that genotype reports do not always predict real-world treatment success or failure. The FOA encourages research that explains and reduces these mismatches so resistance interpretation becomes more reliably predictive.

What types of HIV diversity are emphasized in this opportunity?

A major emphasis is on genotype-phenotype correlations across diverse HIV subtypes and recombinant forms, particularly because many historical datasets and interpretation rules have been heavily influenced by subtype B infections.

Why is there a focus beyond HIV subtype B?

Because subtype B has been a dominant driver of many resistance datasets and rules (commonly in North America and parts of Europe), NIH is encouraging studies that determine whether the same mutations or mutation patterns have similar phenotypic effects in other subtypes and recombinant forms circulating globally.

What kinds of subtype-focused research examples fit the FOA scope?

Examples described include comparing how identical or similar resistance-associated mutations affect drug susceptibility in different genetic backgrounds, and assessing how subtype-specific polymorphisms modify the effect of classic resistance mutations.

What are "minority variants" in HIV drug resistance?

Minority variants are drug-resistant virus populations present at low frequencies that may be missed by standard genotyping but can be detected using more sensitive methods.

Why are minority variants a priority area in this FOA?

The FOA calls for studies evaluating how low-abundance resistant populations relate to treatment outcomes (such as virologic suppression or rebound), especially when patients are placed on recommended regimens. The goal is to determine when minority variants meaningfully predict failure and what detection thresholds or methods are clinically actionable.

What kinds of outcomes are specifically mentioned for minority variant studies?

The opportunity mentions outcomes such as virologic suppression or virologic rebound in relation to recommended antiretroviral regimens.

Does the FOA address cases where genotype results and clinical outcomes do not match?

Yes. The announcement highlights discordance between genotype results and treatment success or failure and encourages applications that investigate why these mismatches occur.

What types of factors are suggested as potential contributors to genotype-outcome discordance?

The FOA lists examples such as adherence patterns, pharmacokinetics and drug-drug interactions, viral fitness and compensatory mutations, reservoir and compartmentalization effects, baseline viral load, host factors, and limitations in current interpretation algorithms.

Can projects study why patients fail therapy despite an apparently susceptible genotype?

Yes. The FOA explicitly encourages investigating why a patient might fail therapy even when genotyping suggests susceptibility.

Can projects study why patients succeed despite resistance-associated mutations?

Yes. The FOA also encourages investigating why a patient might succeed despite mutations that suggest reduced susceptibility.

What kind of study design is particularly encouraged?

The FOA particularly encourages laboratory evaluation of clinical samples paired with strong clinical correlates, meaning studies that go beyond sequencing alone and connect lab-based measurements to well-characterized patient regimens and outcomes.

What laboratory approaches are mentioned as relevant under this FOA?

The announcement mentions phenotypic testing, replication capacity work, and other lab-based assays using clinical samples, linked to treatment regimens and clinical outcomes.

What is meant by a "bench-to-bedside" design in this opportunity?

It refers to integrating laboratory evaluation (bench) of patient-derived samples with clinical data (bedside) so findings translate into improved resistance interpretation and more reliable clinical decision-making.

What funding mechanism does this opportunity use?

This opportunity uses the NIH R01 research project grant mechanism.

What agency is offering this grant opportunity?

The grant opportunity is offered by the National Institutes of Health (NIH).

What is the funding activity category?

The announcement is described as a health-focused funding activity category.

What CFDA numbers are associated with this opportunity?

The CFDA numbers listed are 93.855 and 93.856.

When was the opportunity created and what was the original closing date listed?

The posting creation date was 2017-05-17, and the original closing date listed was 2018-05-07.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. public and private institutions and organizations, such as state and local governments, public and state-controlled and private institutions of higher education, nonprofit organizations (with and without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses.

Are small businesses eligible?

Yes. Small businesses are listed as eligible applicants.

Are for-profit organizations eligible?

Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed separately as eligible.

Are nonprofits without 501(c)(3) status eligible?

Yes. Nonprofit organizations with and without 501(c)(3) status are included as eligible applicants.

Are institutions serving specific populations explicitly mentioned as eligible?

Yes. The FOA explicitly notes eligibility that includes Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, Historically Black Colleges and Universities, and tribally controlled colleges and universities.

Are tribal governments eligible?

Indian/Native American tribal governments that are not federally recognized are explicitly listed among additional eligible applicants.

Are U.S. territories or possessions eligible to apply?

Yes. U.S. territories or possessions are listed among additional eligible applicants.

Are federal agencies eligible applicants?

Yes. Eligible federal agencies are listed among additional eligible applicants.

Are faith-based and community-based organizations eligible?

Yes. Faith-based and community-based organizations are explicitly listed as eligible.

Are non-U.S. (foreign) entities eligible to apply?

Yes. Non-U.S. (foreign) entities and regional organizations are explicitly listed as eligible.

What kinds of applicants does NIH appear to want to attract for this program?

Based on the stated aims and broad eligibility, the program is structured to attract applicants capable of linking molecular resistance data (genotype and phenotype) to meaningful patient outcomes across diverse populations and viral subtypes.